Johnson & Johnson (JNJ DU) stock market data APIs
€174.0352
0.08(0%)
as of December 5, 2025
Try our APIs with
free plan!
Johnson & Johnson Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for JNJ.DU.
Prev. Close
174.0352
Open
174.1148
High
174.1209
Low
173.267
52 wk Range
127.2657-179.56
Market Cap
385 769 M
Dividends (Yield)
0.0222
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Johnson & Johnson data using free add-ons & libraries
Get Johnson & Johnson Fundamental Data
Johnson & Johnson Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Johnson & Johnson News
New
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single infusion as early as second line Data suggest ...
What New Catalysts Are Shaping the Evolving Narrative for Johnson and Johnson Now
Johnson & Johnson’s latest narrative has tilted more constructive, with fresh research nudging its fair value estimate higher from about $200.82 to $202.54 per share and reaffirming a roughly 6.96% ...
Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”
Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it migh...
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
